Safety and effectiveness of biphasic insulin aspart 30/70 (NovoMix® 30) when switching from human premix insulin in patients with type 2 diabetes: subgroup analysis from the 6-month IMPROVE™ observational study

AIMS: IMPROVE™ is an open-label, multinational, non-randomised, 26-week observational study designed to evaluate the safety and effectiveness of biphasic insulin aspart 30 (BIAsp 30) in routine clinical practice. Here, we report data for patients switching to BIAsp 30 from human premixed insulin. ME...

Descripción completa

Detalles Bibliográficos
Autores principales: Shah, S, Benroubi, M, Borzi, V, Gumprecht, J, Kawamori, R, Shaban, J, Shestakova, M, Wenying, Y, Valensi, P
Formato: Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2009
Materias:
Diabetes & Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2705824/
https://www.ncbi.nlm.nih.gov/pubmed/19210701
http://dx.doi.org/10.1111/j.1742-1241.2009.02012.x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2705824/
https://www.ncbi.nlm.nih.gov/pubmed/19210701
http://dx.doi.org/10.1111/j.1742-1241.2009.02012.x

Ejemplares similares